A large US claims analysis linked systemic inflammation to worse outcomes in patients with atherosclerotic cardiovascular disease, tying elevated hsCRP to higher risk of heart attack, stroke, or death. The report estimated a 24% higher risk with hsCRP elevation, and a sharper 62% increase when chronic kidney disease co-occurred. The same analysis associated the inflammation signal with substantially higher healthcare costs, framing hsCRP as an increasingly actionable risk stratifier in real-world care rather than purely a research biomarker. Clinically, the work reinforces the use of inflammation readouts for risk management in cardiovascular patients who may have limited prognostic clarity using traditional factors alone.